Entropy Neurodynamics Executes Agreement for Manufacturing of Proprietary Therapy Candidate; Shares Up 3%

MT Newswires Live

Aug 19

Entropy Neurodynamics (ASX:ENP) executed a development and manufacturing services agreement with BioCina to manufacture its proprietary therapy candidate, TRP-8803, or IV-infused psilocin, according to a Wednesday Australian bourse filing.

BioCina will conduct a program including analytical verification, engineering batch manufacture, followed by GMP placebo and active drug product batches, per the filing. The manufacturing program is expected to take 24 weeks, with real-time stability studies continuing for 24 months.

Entropy is advancing TRP-8803 through a clinical program, including a 72-patient study across eight neuropsychiatric indications of high-unmet clinical need, the filing said. The agreement provides the manufacturing capability to support clinical trials and future regulatory requirements.

The company's shares climbed nearly 3% in recent trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2660241324"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2660241324\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2660241324?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-19 09:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660241324","market":"sh","top_or_hot":-1,"title":"Entropy Neurodynamics Executes Agreement for Manufacturing of Proprietary Therapy Candidate; Shares Up 3%","media":"MT Newswires Live","content":"<html><body><p> Entropy Neurodynamics (ASX:ENP) executed a development and manufacturing services agreement with BioCina to manufacture its proprietary therapy candidate, TRP-8803, or IV-infused psilocin, according to a Wednesday Australian bourse filing.</p><p>BioCina will conduct a program including analytical verification, engineering batch manufacture, followed by GMP placebo and active drug product batches, per the filing. The manufacturing program is expected to take 24 weeks, with real-time stability studies continuing for 24 months.</p><p>Entropy is advancing TRP-8803 through a clinical program, including a 72-patient study across eight neuropsychiatric indications of high-unmet clinical need, the filing said. The agreement  provides the manufacturing capability to support clinical trials and future regulatory requirements.</p><p>The company's shares climbed nearly 3% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Entropy Neurodynamics Executes Agreement for Manufacturing of Proprietary Therapy Candidate; Shares Up 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEntropy Neurodynamics Executes Agreement for Manufacturing of Proprietary Therapy Candidate; Shares Up 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-19 09:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Entropy Neurodynamics (ASX:ENP) executed a development and manufacturing services agreement with BioCina to manufacture its proprietary therapy candidate, TRP-8803, or IV-infused psilocin, according to a Wednesday Australian bourse filing.</p><p>BioCina will conduct a program including analytical verification, engineering batch manufacture, followed by GMP placebo and active drug product batches, per the filing. The manufacturing program is expected to take 24 weeks, with real-time stability studies continuing for 24 months.</p><p>Entropy is advancing TRP-8803 through a clinical program, including a 72-patient study across eight neuropsychiatric indications of high-unmet clinical need, the filing said. The agreement  provides the manufacturing capability to support clinical trials and future regulatory requirements.</p><p>The company's shares climbed nearly 3% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2660241324","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2660241324","pubTimestamp":1787101292,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Entropy Neurodynamics  executed a development and manufacturing services agreement with BioCina to manufacture its proprietary therapy candidate, TRP-8803, or IV-infused psilocin, according to a Wednesday Australian bourse filing.BioCina will conduct a program including analytical verification, engineering batch manufacture, followed by GMP placebo and active drug product batches, per the filing. The manufacturing program is expected to take 24 weeks, with real-time stability studies continuing for 24 months.Entropy is advancing TRP-8803 through a clinical program, including a 72-patient study across eight neuropsychiatric indications of high-unmet clinical need, the filing said. The agreement  provides the manufacturing capability to support clinical trials and future regulatory requirements.The company's shares climbed nearly 3% in recent trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","ENP.AU":"Entropy Neurodynamics Limited"},"translate_title":"Entropy Neurodynamics 执行专有候选疗法的制造协议；股价上涨 3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENP.AU":1},"content_text":"Entropy Neurodynamics (ASX:ENP) executed a development and manufacturing services agreement with BioCina to manufacture its proprietary therapy candidate, TRP-8803, or IV-infused psilocin, according to a Wednesday Australian bourse filing.BioCina will conduct a program including analytical verification, engineering batch manufacture, followed by GMP placebo and active drug product batches, per the filing. The manufacturing program is expected to take 24 weeks, with real-time stability studies continuing for 24 months.Entropy is advancing TRP-8803 through a clinical program, including a 72-patient study across eight neuropsychiatric indications of high-unmet clinical need, the filing said. The agreement  provides the manufacturing capability to support clinical trials and future regulatory requirements.The company's shares climbed nearly 3% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}